Although an extensive review of the literature about the effects of thyromimetics on hepatic steatosis and insulin sensitivity is beyond the scope of this review, it is worth noting that given the weight-reducing potential of TR activation, both sobetirome as well as eprotirome have been studied as therapeutic strategies for the treatment of metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), in rodents. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.